These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29319282)

  • 21. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.
    Cabaleiro T; Prieto-Pérez R; Navarro R; Solano G; Román M; Ochoa D; Abad-Santos F; Daudén E
    Pharmacogenomics J; 2016 Aug; 16(4):336-40. PubMed ID: 26194362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neurological symptoms following infusion of infliximab].
    Bebe AC; Harboe KM; Nøjgaard C
    Ugeskr Laeger; 2012 Oct; 174(40):2388-90. PubMed ID: 23031302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
    Downs AM
    Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
    [No Abstract]   [Full Text] [Related]  

  • 29. TNFα inhibitor-induced urticaria: a class effect.
    Canu D; Seneschal J; Milpied B; Taieb A; Darrigade AS
    Eur J Dermatol; 2019 Oct; 29(5):543-544. PubMed ID: 31789277
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
    Wahie S; Alexandroff A; Reynolds NJ
    Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of psoriasis: focus on clinic-based management with infliximab.
    de Eusebio E; Armario-Hita JC; de Miquel VA
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S5-16. PubMed ID: 24777571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab.
    Vestita M; Guida S; Mazzoccoli S; Loconsole F; Foti C
    Eur J Dermatol; 2015; 25(3):272-3. PubMed ID: 25786592
    [No Abstract]   [Full Text] [Related]  

  • 34. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 35. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
    Hession MT; Gottlieb AB
    J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 37. Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients.
    Chabbert C; Adamski H; Guillet G; Sassolas B; Misery L; Perrinaud A; Machet L; Quereux G; Esteve E; Solau-Gervais E; Saraux A; Polard E; Lesimple T; Le Gall F; Dreno B; Dupuy A
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1540-4. PubMed ID: 24329560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.
    Semble AL; Davis SA; Feldman SR
    Am J Clin Dermatol; 2014 Feb; 15(1):37-43. PubMed ID: 24281790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric MALT lymphoma in a patient receiving infliximab for psoriasis.
    Girard C; Guillot B; Bessis D
    Br J Dermatol; 2008 Aug; 159(2):497-8. PubMed ID: 18547313
    [No Abstract]   [Full Text] [Related]  

  • 40. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.